Login to Your Account

Vedanta embarks on testing new class of C. diff therapy

By Michael Fitzhugh
Staff Writer

Thursday, December 7, 2017

Vedanta Biosciences Inc. has begun a phase Ia/Ib trial of VE-303, its oral immune-modulating bacterial consortia therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription